Ardelyx (ARDX) Tops Q2 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P 500, Nasdaq futures inch up as markets monitor Hormuz situation
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil edges higher as Iran tempers hopes of swift Hormuz reopening
- HPE stock surges 5% as Morgan Stanley upgrades, pointing to ~30% upside
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Ardelyx Reports Second Quarter 2015 Financial Results
August 12, 2015 6:00 AM EDTFREMONT, Calif., Aug. 12, 2015 /PRNewswire/ --Â Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.
"We have made significant progress towards our goal of becoming a fully-integrated bio-pharmaceutical company,'" said Mike Raab, President and Chief Executive Officer. "Under our leadership, tenapanor's clinical development is accelerating, with a Phase 3 clinical program in IBS-C and a Phase 2b dosing trial in hyperphosphatemia patients on... More
